Evolva completes Allylix acquisition

This acquisition was announced on 18 November 2014


Allylix will be a wholly-owned subsidiary of Evolva

Evolva Holding announces the completion of the acquisition of Allylix, after which the aquired comapany will be a wholly-owned subsidiary of Evolva.

This transaction is in return for an overall consideration of 46 million newly-issued Evolva shares (c. 14.1 percent of Evolva post transaction). Part of these shares, currently estimated at approx. 6 million shares, will be sold over a period of time after closing, to offset certain liabilities and transaction expenses of Allylix. Shares allocated to the Allylix security holders will be subject to a staggered lock-up, such that the shares will be released in twelve tranches of approx. 3 million shares each, during the first year after the closing of the transaction.

The SIX Swiss Exchange has approved the listing of the new Evolva shares and trading in the new shares on the Main Standard of SIX is expected to commence soon.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email